-
Court Denies Renovaro Motion for an Expedited Trial in July
-
Predictive Oncology Inc. (POAI) Says Breakthrough Coincides with Regeneron's $256M 23andMe Acquisition
-
Predictive Oncology Inc. (POAI) Misses Q1 EPS by 32c
-
Renovaro Biosciences (RENB) Provides Update to Definitive Agreement with Predictive Oncology (POAI)
-
Predictive Oncology (POAI) Announces Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
-
Predictive Oncology (POAI) Partners with Switzerland-Based Tecan Group Ltd. to Expand High-Throughput Drug Screening to Include Human Tumor Spheroids Using Automated Imaging and 3D Analysis
-
Predictive Oncology Inc. (POAI) Announces Planned European Launch of its ChemoFx® Treatment Selection Marker and Tumor Profiling Assay
-
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Predictive Oncology Inc. Buyout
-
Predictive Oncology (POAI) to be Acquired by Renovaro
-
Predictive Oncology Inc. (POAI) Halted, News Pending
-
Predictive Oncology (POAI): Comprehensive due diligence remains ongoing with several parties
-
Predictive Oncology Inc. (POAI) Misses Q3 EPS by 36c
-
Predictive Oncology (POAI) Study Demonstrates Long-Term Stability and Viability of Proprietary Biobank of Primary Tumor Specimens for Pharmaceutical Drug Discovery
-
H.C. Wainwright Starts Predictive Oncology (POAI) at Buy
-
Predictive Oncology Inc. (POAI) Files for 1.98M Share Offering by Selling Stockholders
-
Predictive Oncology Inc. (POAI) Misses Q2 EPS by 68c
-
Predictive Oncology (POAI) Expands the Application of its Live-Cell Tumor Platform to De-Risk Drug Discovery and Accelerate Pipeline Development
-
Predictive Oncology (POAI) Announces Exercise of Warrants for $1.26 Million Gross Proceeds
-
Predictive Oncology (POAI) Enters Biomarker Discovery Market After Successful Retrospective Ovarian Cancer Study Yields Compelling Results
-
Predictive Oncology (POAI) Develops Novel Stem Cell Expression System for the Production of Functional and Stable G-Protein Coupled Receptors

